<< Back to News

System Formulary Update
Integrase Inhibitors Class Standardization

Situation:

The INSTI class review standardization was approved for addition to the health system formulary at the August 2023 System Pharmacy and Therapeutics Committee Meeting.

Background:

The following products were reviewed: abacavir-dolutegravir-lamivudine tablets, abacavir-dolutegravir-lamivudine tablets for oral suspension, bictegravir-emtricitabine-tenofovir alafenamide tablets, cabotegravir tablets, cabotegravir extended-release injection, cabotegravir-rilpivirine extended-release injection, dolutegravir tablets, dolutegravir tablets for oral suspension, dolutegravir-lamivudine tablets, dolutegravir-rilpivirine tablets, elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide tablets, elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil tablets, raltegravir tablets, raltegravir chewable tablets, raltegravir powder for oral suspension. 

Assessment/Recommendations:

System P&T voted to include the following product from the UNC Health Medication Formulary:

• Bictegravir-emtricitabine-tenofovir alafenamide 50-200-25 mg tablet
• Cabotegravir 600 mg/3 mL extended-release injection
• Cabotegravir-rilpivirine 400 mg-600 mg/4 mL extended-release injection
• Cabotegravir-rilpivirine 600 mg-900 mg/6 mL extended-release injection
• Dolutegravir 50 mg tablet
• Elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide 150-150-200-10 mg tablet

Note: Stock of this formulary product may vary at individual entities 

Formulary/Epic Changes will Go-Live on Tuesday, October 17, 2023